SCHEMBL6793672

SCHEMBL6793672

O=C(COc1ccc(-c2ccccc2C(=O)Nc2ccc(NCCc3ccccn3)cc2)cc1)NS(=O)(=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.45
KMT2A Q03164 3/20 0.44
RAB9A P51151 2/20 0.44
BCL2L1 Q07817 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SGMS1 Q86VZ5 3/20 0.42
LMNA P02545 2/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 2/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6793525 0.90 RAB9A (0.45) PKMKMT2ARAB9ASMN1; SMN2LMNA
SCHEMBL6789216 0.89 SMN1; SMN2 (0.48) KMT2ARAB9ASMN1; SMN2LMNAMEN1
SCHEMBL6792821 0.87 GAA (0.48) KMT2ARAB9ASMN1; SMN2LMNAMEN1
SCHEMBL6794937 0.86 NPC1 (0.48) PKMKMT2ARAB9ASMN1; SMN2LMNA
SCHEMBL6792973 0.84 NPC1 (0.47) PKMKMT2ARAB9ASMN1; SMN2LMNA
SCHEMBL6796259 0.83 NPC1 (0.50) PKMKMT2ARAB9ASMN1; SMN2LMNA
SCHEMBL6792178 0.83 MAPT (0.50) PKMKMT2ARAB9ASMN1; SMN2LMNA
SCHEMBL6795010 0.82 RAB9A (0.55) PKMKMT2ARAB9ASMN1; SMN2LMNA
SCHEMBL6793923 0.82 F2 (0.42) PKMKMT2ARAB9ABCL2L1LMNA
SCHEMBL6791511 0.82 HTT (0.57) KMT2ARAB9ALMNAMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 PKM 3447/4885KMT2A 2457/4885RAB9A 3707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.